SCORE Search Results Details for Application 10591347 and Search Result 20110118_143624_seq2sub1633a.rng

 Score Home
 Retrieve Application
 SCORE System
 SCORE
 Comments /

 Page
 List
 Overview
 FAQ
 Suggestions

This page gives you Search Results detail for the Application 10591347 and Search Result 20110118_143624_seq2sub1633a.rng.

Go Back to previous page

GenCore version 6.3 Copyright (c) 1993 - 2011 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 18, 2011, 22:29:00; Search time 1520 Seconds

(without alignments)

47792.104 Million cell updates/sec

Title: SEQ2SUB1633A

Perfect score: 3424

Sequence: 1 aggatcagaacaatgcctcc.....taaactagttcatttcaaaa 3424

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 18225500 seqs, 10608060480 residues

Total number of hits satisfying chosen parameters: 36451000

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: N_Geneseq_201023:*

1: genesegn1:*

2: genesegn2:*

3: genesegn3:*

4: genesegn4:*

5: geneseqn5:*

6: geneseqn6:*

7: genesean7:*

8: geneseqn8:*

9: geneseqn9:*

SUMMARIES

응 Result Query No. Match Length DB ID Description Score 3422.4 99.9 3424 AAS14365 Aas14365 cDNA enco 2 3422.4 99.9 Ab159523 Human pho 3424 1 ABL59523 3 3422.4 99.9 3424 2 Ade85076 Farnesyl ADE85076 4 ADZ00490 3422.4 99.9 3424 4 Adz00490 p110-beta 5 3422.4 99.9 3424 AEH10445 Aeh10445 PIK3CA cD 6 3422.4 99.9 3424 4 AED31618 Aed31618 cDNA (SEO 7 3422.4 99.9 3424 AEG93388 Aeg93388 Human tum 8 3410.4 99.6 Aaq51156 Human p11 3412 1 AAQ51156 9 3410.4 99.6 3412 Aed31617 cDNA (SEQ 4 AED31617 10 3410.4 99.6 3423 3 ADU05935 Adu05935 Novel bro 3338 97.5 3426 Arc02473 DNA fragm 11 6 ARC02473 12 3338 97.5 3724 AEK54940 Aek54940 Human PIK 5 13 3338 97.5 3724 AER29796 Aer29796 Breast ca 7 14 3338 97.5 3724 ARV60468 Arv60468 Human PIK 3338 97.5 3724 7 Arw65283 Human PIK 15 ARW65283 7 16 3338 97.5 3724 ATM52123 Atm52123 Human PIK 17 3338 97.5 3724 7 ATS16021 Ats16021 Human pho 18 3338 97.5 3724 8 AWY98731 Awy98731 Human PIK 97.5 3724 19 3338 8 AWY98891 Awy98891 Human PIK 3338 20 97.5 3724 AWY98894 Awy98894 Human PIK 21 3338 97.5 3724 9 Axu25358 Human pho AXU25358 22 3338 97.5 3724 9 Aye41305 Human PIK AYE41305 23 3279.4 95.8 4326 8 Awy98838 Human PIK AWY98838 24 3205.4 93.6 3207 2 ADH68168 Adh68168 DNA encod 25 3205.4 93.6 3207 4 AEF64785 Aef64785 Human pho 26 3145 91.9 7923 8 AW077361 Awo77361 Expressio 7 27 3144.6 91.8 3207 Arl60529 Human pho ARL60529 28 Aek13519 Phosphati 3143 91.8 3207 4 AEK13519 29 3141.4 91.7 3207 4 AEK13514 Aek13514 Phosphati 30 3141.4 91.7 3207 4 Aek13515 Phosphati AEK13515 Aaq57012 PtdIns 3-31 3137 91.6 3498 1 AAQ57012 32 91.1 Aek13511 Phosphati 3118.8 3210 4 AEK13511 33 3007 87.8 3207 1 AAQ51155 Aaq51155 p110 cDNA Awy98836 Human PIK 34 2640.6 77.1 8 3207 AWY98836 35 2640.6 77.1 3207 8 AWY98892 Awy98892 Human PIK 36 49.3 2 1687.6 8421 ACN43202 Acn43202 Human dia 37 1515.8 44.3 2397 1 AFS82080 Afs82080 Human tra 34.6 38 1183.4 1792 3 ADR39810 Adr39810 Human kin 697.4 20.4 39 2872 8 Awy98893 Human PIK AWY98893 40 16.5 741 1 Aaa02190 Human col 564 AAA02190 41 564 16.5 741 4 Agd33161 Human pol AGD33161 42 530 15.5 716 4 AEK18520 Aek18520 Human PIK 43 459.2 13.4 3213 Aac65690 Human PI3 AAC65690

44 459.2 13.4 3213 1 AAS14366 Aas14366 cDNA enco 45 459.2 13.4 3213 1 ABV78026 Abv78026 Hypoxia-r

ALIGNMENTS

```
RESULT 1
AAS14365
ID
     AAS14365 standard; cDNA; 3424 BP.
XX
AC
     AAS14365;
XX
     11-JUN-2007 (revised)
DT
     12-MAR-2002 (first entry)
DT
XX
DE
     cDNA encoding human p110alpha isoform of PI3-kinase.
XX
     Human; phosphatidylinositol 3-kinase; PI3K; p110alpha isoform; LASP-1;
ΚW
KW
     cancer; inflammatory disease; ophthalmic disorder; SH3 domain;
     autoimmune disease; inflammatory bowel disease; bacterial pneumonia;
KW
     Type I diabetes mellitus; cytostatic; immunosuppressive; ss.
KW
XX
OS
     Homo sapiens.
XX
                     Location/Qualifiers
FΗ
     Key
     CDS
                     13. .3219
FT
FT
                     /*tag= a
FT
                     /product= "p110alpha isoform of PI3-kinase"
XX
PN
     WO200185986-A2.
XX
     15-NOV-2001.
PD
XX
PF
     10-MAY-2001; 2001WO-US015065.
XX
PR
     10-MAY-2000; 2000US-0203346P.
XX
PA
     (ICOS-) ICOS CORP.
XX
PΙ
     Sadhu C;
XX
     WPI; 2002-075252/10.
DR
     P-PSDB; AAU09687.
DR
     PC:NCBI; qi472990.
DR
     PC_ENCPRO:NCBI; gi472991.
DR
XX
PT
     Identifying a modulator of p110delta polypeptide binding to SH3 domain-
PΤ
     containing polypeptides e.g. LASP-1, comprising allowing the binding
```

```
partners to interact in the presence and absence of a test compound.
PΤ
XX
    Example 1; Page 55-60; 85pp; English.
PS
XX
CC
    The present invention relates to identifying a modulator of the
    phosphatidylinositol 3-kinase (PI3K; p110delta) enzyme that binds to the
CC
CC
    catalytic subunit via a SH3 domain-containing polypeptide such as LASP-1.
CC
    Also described are methods of assaying the specific binding affinity of
CC
    the PI3-kinase binding partner. Such modulators are useful for the
    treatment of diseases characterised by the undesirable or excessive
CC
    activity of PI3Kdelta. For example the modulators can be used for
CC
    inhibiting the growth or proliferation of cancer cells (e.g. malignant
CC
    neoplasms of lymphoid and reticuloendothelial tissues, Hodgkin's
CC
CC
    lymphoma, leukaemias), inflammatory diseases (e.g. rheumatoid arthritis),
    ophthalmic disorders (e.g. allergic conjunctivitis), autoimmune diseases
CC
    (e.g. systematic lupus erythematosus), inflammatory bowel diseases (e.g.
CC
CC
    chronic inflammatory bowel disease), inflammatory dermatoses (e.g.
    contact dermatitis; central or peripheral nervous system inflammatory
CC
    disorders (e.g. meningitis), bacterial pneumonia, and Type I diabetes
CC
CC
    mellitus. The present sequence encodes for human p110alpha isoform of
CC
    PI3k
CC
CC
    Revised record issued on 11-JUN-2007: Enhanced with precomputed
CC
    information from BOND.
XX
    Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;
SQ
 Query Match
                       99.9%;
                              Score 3422.4;
                                           DB 1; Length 3424;
 Best Local Similarity
                       99.9%;
 Matches 3423; Conservative 0; Mismatches
                                             1;
                                                 Indels
                                                          0; Gaps
                                                                    0;
          1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Qу
            Db
          1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
         61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
            61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Db
Qу
        121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
            121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Db
        181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Qу
            181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Db
        241 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA 300
Qу
```

961 TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA 1020

Qy	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Db	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Qy	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Db	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Qy	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Qy	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Qу	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Db	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Qу	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Qу	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Db	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Qу	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Qу	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621	CGAGATCCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Qy	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Db	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740

Qу

2401 AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT 2460

2461 ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT 2520

Db	2461		2520
Qy	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Db	2521		2580
Qу	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2581		2640
Qy	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Qy	2701		2760
Db	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Qy	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Qy	2821		2880
Db	2821		2880
Qy	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Qy	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	2941		3000
Qy	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Qy	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Qy	3121	GAGTATTTCATGAAACAAATGAATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180
Db	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAATGGAT	3180
Qy	3181	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA	3240

```
Db
        3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
        3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
QУ
            3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Db
        3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
QУ
            Db
        3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
Qу
        3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
            Db
        3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
        3421 AAAA 3424
QУ
            Db
        3421 AAAA 3424
RESULT 2
ABL59523
ID
    ABL59523 standard; cDNA; 3424 BP.
XX
AC
    ABL59523;
XX
DT
    11-JUN-2007 (revised)
    16-JUL-2002 (first entry)
DT
XX
DE
    Human phosphatidylinositol-3-kinase catalytic alpha cDNA SEQ ID NO:23.
XX
KW
    Human; phosphatidylinositol-3-kinase catalytic alpha; enzyme; tumour;
    lipid associated gene; lipid metabolism; lipid synthesis;
ΚW
    chromosome 3q26.3; gene; ss.
KW
XX
OS
    Homo sapiens.
XX
PN
    W0200227028-A1.
XX
PD
    04-APR-2002.
XX
    27-SEP-2001; 2001WO-US030366.
PF
XX
    28-SEP-2000; 2000US-00676052.
PR
XX
    (ATAI-) ATAIRGIN TECHNOLOGIES INC.
PA
XX
PΙ
    Skinner MK, Patton JL, Chaudhary J;
XX
    WPI: 2002-405056/43.
DR
```

```
PC:NCBI; qi472990.
DR
    PC ENCPRO: NCBI; qi472991.
DR
XX
    Identifying tumor characteristics in a tissue sample taken from a
PΤ
    patient, involves determining the copy number or expression level of
PΤ
    genes associated with lipid metabolism, synthesis or action.
PT
XX
    Example 1; Page 82-83; 113pp; English.
ΡS
XX
CC
    The present invention describes a method for identifying tumour
CC
    characteristics, comprising measuring a copy number or expression level
    of at least two genes associated with lipid metabolism, synthesis, or
CC
CC
    action in cells from a patient tissue sample, and comparing the results
    with a copy number or expression level of the genes in a normal cell.
CC
    Also described is an array of nucleic acid polymers immobilised on a
CC
    solid support, comprising a solid support, at least two different nucleic
CC
CC
    acid polymers which are each specific for a different gene associated
    with lipid metabolism, synthesis or action, where each nucleic acid
CC
    polymer is located at a predetermined position on the solid support, and
CC
CC
    the array comprises nucleic acid polymers which are specific for less
    than 100 genes other than the selected genes. The method is useful for
CC
CC
    determining tumour characteristics in a tissue sample taken from a
CC
    patient. The present sequence represents a human lipid-associated gene
CC
    related cDNA sequence, which is used in the exemplification of the
    present invention
CC
CC
CC
    Revised record issued on 11-JUN-2007: Enhanced with precomputed
CC
    information from BOND.
XX
    Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;
SO
 Query Match
                       99.9%;
                              Score 3422.4; DB 1; Length 3424;
 Best Local Similarity
                       99.9%;
 Matches 3423; Conservative 0; Mismatches
                                              1;
                                                  Indels
                                                           0;
                                                                      0;
                                                              Gaps
          1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Qу
             1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Db
          61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
            61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Db
         121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Qу
             121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Db
         181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Qу
```

Qy	961	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA	1020
Db	961	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA	1020
Qу	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Db	1021		1080
Qу	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Db	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Qу	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Qу	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Db	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Qу	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Qу	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Db	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Qу	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Qу	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1561		1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621		1680

Qу

2341 AGGCCACTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAAC 2400

2401 AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT 2460

Db	2401		2460
Qy	2461	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2520
Db	2461		2520
Qy	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Db	2521		2580
Qy	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2581		2640
Qy	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Qу	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Db	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Qy	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Qу	2821	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Db	2821	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Qу	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Qу	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Qу	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Qy	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Qy	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180

```
Db
       3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
       3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
QУ
            3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Db
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
QУ
            Db
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Qу
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
            3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
Db
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Qу
            3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Db
       3421 AAAA 3424
Qу
            3421 AAAA 3424
Db
RESULT 3
ADE85076
ID
    ADE85076 standard; DNA; 3424 BP.
XX
AC
    ADE85076;
XX
    11-JUN-2007 (revised)
DT
    29-JAN-2004 (first entry)
DT
XX
    Farnesyl transferase inhibitor modulated leukemia associated gene #295.
DE
XX
    ss; cytostatic; farnesyl transferase inhibitor; gene expression;
KW
    quinolinone; leukemia; cancer.
ΚW
XX
OS
    Homo sapiens.
XX
    WO2003038129-A2.
PΝ
XX
PD
    08-MAY-2003.
XX
PF
    30-OCT-2002; 2002WO-US034784.
XX
    30-OCT-2001; 2001US-0338997P.
PR
    30-OCT-2001; 2001US-0340081P.
PR
PR
    30-OCT-2001; 2001US-0340938P.
    30-OCT-2001; 2001US-0341012P.
PR
```

```
XX
PΑ
    (ORTH ) ORTHO CLINICAL DIAGNOSTICS INC.
XX
    Raponi M;
PΙ
XX
    WPI; 2003-513497/48.
DR
DR
    PC:NCBI; gi472990.
    PC_ENCPRO:NCBI; qi472991.
DR
XX
PT
    Determining whether a patient will respond to treatment with a farnesyl
PT
    transferase inhibitor, by analyzing the expression of gene that is
    differentially modulated in the presence of the inhibitor.
PT
XX
PS
    Disclosure; SEQ ID NO 295; 346pp; English.
XX
CC
    The invention relates to a method of determining whether a patient will
CC
    respond to treatment with a farnesyl transferase inhibitor (FTI), by
    analyzing the expression of gene that is differentially modulated in the
CC
CC
    presence of an FTI. The method is useful for determining whether a
CC
    patient will respond to treatment with a FTI such as (B)-6-[amino(4-
CC
    chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-
CC
    methyl-2-(1H) quinolinone, monitoring the therapy of a patient, treating a
CC
    patient with leukemia with FTI if the analysis indicates that the patient
CC
    will respond. This sequence corresponds to a gene whose expression may be
    modulated in the presence of FTI.
CC
CC
CC
    Revised record issued on 11-JUN-2007: Enhanced with precomputed
CC
    information from BOND.
XX
    Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;
SO
 Query Match
                       99.9%;
                              Score 3422.4; DB 2; Length 3424;
 Best Local Similarity
                       99.9%;
 Matches 3423; Conservative
                             0; Mismatches
                                             1;
                                                 Indels
                                                          0;
                                                                     0;
                                                              Gaps
          1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
Qу
            1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Db
Qу
         61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
            61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Db
         121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Qу
            121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Db
Qу
         181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
```

Qy	961	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA	1020
Db	961	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA	1020
Qу	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Db	1021		1080
Qу	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Db	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Qу	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Qу	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Db	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Qу	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Qу	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Db	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Qу	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Qу	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1561		1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621		1680

Qу

2341 AGGCCACTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAAC 2400

2401 AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT 2460

Db	2401		2460
Qy	2461	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2520
Db	2461		2520
Qу	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Db	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Qу	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Qу	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Qу	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Db	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Qу	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Qy	2821	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Db	2821	TTTTTGGATCACAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Qy	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Qy	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	2941	TTTGAGAGGTTTCAGGAGATGTTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Qу	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Qy	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Qy	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180

```
Db
       3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
       3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
QУ
           3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Db
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
QУ
           Db
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Qу
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
           3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
Db
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
QУ
           3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Db
       3421 AAAA 3424
QУ
           3421 AAAA 3424
Db
RESULT 4
ADZ00490
ID
    ADZ00490 standard; cDNA; 3424 BP.
XX
AC
    ADZ00490;
XX
    11-JUN-2007 (revised)
DT
    16-JUN-2005 (first entry)
DT
XX
DE
    p110-beta coding sequence.
XX
    ss; Anorectic; Antidiabetic; p110-beta; phosphoinositide 3-kinase; p85;
KW
    ras; insulin resistance; obesity; gene.
ΚW
XX
OS
    Homo sapiens.
XX
FH
    Key
                 Location/Qualifiers
                 13. .3219
FT
    CDS
FT
                 /*tag= a
XX
PN
    WO2005031341-A2.
XX
    07-APR-2005.
PD
XX
PF
    28-SEP-2004; 2004WO-IB003926.
XX
```

```
29-SEP-2003; 2003US-0507226P.
PR
    13-JUL-2004; 2004US-0587333P.
PR
XX
PA
    (PFIZ ) PFIZER HEALTH AB.
XX
PΙ
    Bougneres P;
XX
    WPI; 2005-273421/28.
DR
DR
    P-PSDB; ADZ00491.
DR
    GENBANK; Z29090.
DR
    PC:NCBI; gi472990.
    PC_ENCPRO:NCBI; gi472991.
DR
XX
PΤ
    Predicting a subject's likelihood of developing insulin resistance,
    useful for treating insulin resistance and obesity, comprises determining
PT
    in a subject the identity of an allele at position 100 of a specific
PT
PT
    sequence.
XX
ΡS
    Disclosure; SEQ ID NO 2; 88pp; English.
XX
CC
    This sequence represents the p110-beta gene. p110-beta is a catalytic
CC
    subunit of a phosphoinositide 3-kinase, which also comprises a regulatory
CC
    subunit of about 85 kD. The p110 protein comprises a kinase domain at the
    C-terminus, and a p85 and ras binding domain at the N-terminus. The
CC
    method of the invention for predicting a subject's likelihood of
CC
    developing insulin resistance comprises determining in a subject the
CC
    identity of the nucleotide present at a position corresponding to
CC
    position -359 of the p110-beta gene , where the allele comprising the
CC
CC
    nucleotide is correlated with an increased or decreased likelihood of
    developing insulin resistance. The method of the invention is useful for
CC
CC
    treating obesity and insulin resistance and for assessing and conducting
CC
    clinical trials of medicaments.
CC
CC
    Revised record issued on 11-JUN-2007 : Enhanced with precomputed
CC
    information from BOND.
XX
SO
    Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;
 Query Match
                        99.9%;
                                Score 3422.4; DB 4; Length 3424;
 Best Local Similarity
                        99.9%;
 Matches 3423; Conservative
                            0; Mismatches
                                                1;
                                                    Indels
                                                              0;
                                                                 Gaps
                                                                         0;
           1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
Qу
             1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
Db
          61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
             Db
          61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
```

Qy	121	CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC	180
Db	121	CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC	180
Qy	181	CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA	240
Db	181	CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA	240
Qy	241	GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA	300
Db	241	GCAGAAAGGGAAGATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA	300
Qy	301	CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA	360
Db	301	CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA	360
Qy	361	ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA	420
Db	361	ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA	420
Qy	421	CAGGACTTCCGAAGAAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT	480
Db	421	CAGGACTTCCGAAGAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT	480
Qy	481	AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG	540
Db	481	AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG	540
Qy	541	CTGCCAAAGCACATATATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA	600
Db	541	CTGCCAAAGCACATATATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA	600
Qy	601	ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTG	660
Db	601	ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTG	660
Qy	661	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTAGAAGTATGTTGCTATCATCT	720
Db	661	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTAGAAGTATGTTGCTATCATCT	720
Qy	721	GAACAATTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGA	780
Db	721	GAACAATTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGA	780
Qy			010
$\Sigma \lambda$	781	TGTGATGAATACTTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGT	040

Db	1561		1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621	CGAGATCCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Qу	1681		1740
Db	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Qу	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Qу	1801		1860
Db	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Qу	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	1861	CGGTGCTTGGAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Qу	1921		1980
Db	1921		1980
Qу	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Qу	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Db	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Qу	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Db	2101		2160
Qу	2161	GACATTCTCAAACAGGAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Db	2161	GACATTCTCAAACAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTAGTT	2220
Qу	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Db	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Qy	2281	CCTGCTCATCAACTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAA	2340

Db

3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060

```
3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Qу
           3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Db
       3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Qу
           3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Db
       3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Qу
           3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Db
Qу
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
           3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Db
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
QУ
           Db
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Qy
           Db
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Qу
       3421 AAAA 3424
           3421 AAAA 3424
Db
RESULT 5
AEH10445
ID
   AEH10445 standard; cDNA; 3424 BP.
XX
AC
   AEH10445;
XX
DT
   11-JUN-2007
              (revised)
DT
    01-JUN-2006
              (first entry)
XX
DE
   PIK3CA cDNA SEQ ID 831.
XX
KW
   gene expression; prognosis; diagnosis; DNA microarray;
    colorectal disease; colon tumor; colorectal tumor; cytostatic;
KW
    gastrointestinal disease; neoplasm; ss.
ΚW
XX
   Unidentified.
OS
XX
PN
   WO2005054508-A2.
XX
```

PD

PΤ

PT PT

XX PS

XX CC

CC

CC

CC CC

CC

CC

CC CC

CC

CC

CC CC

CC

CC

CC

CC

CC

CC

CC CC

CC

CC CC

CC

CC CC 16-JUN-2005.

```
XX
     01-DEC-2004; 2004WO-IB004323.
PF
XX
PR
     01-DEC-2003; 2003US-0525987P.
     01-DEC-2004; 2004US-00000688.
PR
XX
     (IPSO-) IPSOGEN.
PA
PA
     (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
     (PAOL-) INST PAOLI CALMETTES IPC.
PA
XX
PΙ
     Bertucci F, Houlgatte R,
                                Birnbaum D, Debono S;
XX
     WPI; 2005-435408/44.
DR
     PC:NCBI; qi472990.
DR
XX
```

Analyzing differential gene expression associated with histopathologic features of colorectal disease, involves detecting overexpression or underexpression of pool of polynucleotide sequences in colon tissues.

Claim 1; SEQ ID NO 831; 154pp; English.

The invention describes a method of analyzing (M1) differential gene expression associated with histopathologic features of colorectal disease, comprising detecting overexpression or underexpression of a pool of polynucleotide sequences in colon tissues, the pool selected in each of predefined polynucleotide sequence sets chosen from any one of 644 sequence sets comprising combinations of SEQ ID No. 1-1596, fully defined in the specification. Also described are: a polynucleotide library (I) useful for the molecular characterization of a colon cancer, comprising or corresponding to a pool of polynucleotide sequences either overexpressed or underexpressed in colon tissue, the pool corresponding to all or part of the polynucleotide sequence chosen from PS1; and assigning (M2) a therapeutic regimen to patient with histopathological features of colorectal disease, e.g. colon cancer, comprising classifying the patient having a poor prognosis or a good prognosis on the basis of (M1), assigning the patient a therapeutic regimen, the therapeutic regiment comprising no adjuvant chemotherapy if the patient is lymph node negative and is classified as having a good prognosis or comprising chemotherapy if the patient has any other combination of lymph node status and expression profile. (M1) is useful for analyzing differential gene expression associated with histopathologic features of colorectal disease. (M1) is useful for analyzing differential gene expression associated with colon tumors, visceral metastases in colon cancer, lymph node metastases in colon cancer, MSI phenotype in colon cancer, location of primary colorectal carcinoma, in colon cancer, and survival and death of patient in colon cancer, where the analysis comprises detection of overexpression or underexpression of pool of polynucleotide sequences in colon tissue, the pool corresponding to specific combination of

```
CC
    polynucleotide sequences from PS1, as given in the specification. (M1) is
    useful for detecting, diagnosing, staging, classifying, monitoring or
CC
    predicting conditions associated with colorectal cancer. (M1) is useful
CC
CC
    for prognosis or diagnosis or colon cancer or for monitoring the
CC
    treatment of a patient with colon cancer, which involves implementing
    (M1) on nucleic acids from the patient. (M1) is useful for
CC
CC
    differentiating a normal cell from a cancer cell, which involves
CC
    implementing (M1) on nucleic acids from the cells. (M1) is useful for
CC
    selecting appropriate doses and/or schedule of chemotherapeutics and/or
CC
    (bio)pharmaceuticals and/or target agents e.g. Irinotecan, 5-fluorouracil
CC
    and methotrexate. This sequence represents a polynucleotide identified in
    the analysis of differential gene expression associated with
CC
CC
    histopathological features of colorectal disease. Note: The sequence data
CC
    for this patent is not represented in the printed specification but is
    based on sequence information supplied by the European Patent Office.
CC
CC
CC
    Revised record issued on 11-JUN-2007: Enhanced with precomputed
CC
    information from BOND.
XX
SQ
    Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;
 Query Match
                      99.9%;
                             Score 3422.4;
                                          DB 4; Length 3424;
 Best Local Similarity
                      99.9%;
 Matches 3423; Conservative
                            0;
                                Mismatches
                                                                   0;
                                            1;
                                                Indels
                                                        0;
                                                            Gaps
Qу
          1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
            1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Db
         61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
            61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Db
        121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Qу
            121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Db
        181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Qу
            181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Db
Qу
        241 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA 300
            241 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA 300
Db
        301 CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 360
Qу
            Db
        301 CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 360
```

1081 CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA 1140

Db	1081		1140
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Qу	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Qy	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Db	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Qу	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Qу	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Db	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
QУ	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Qу	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621	CGAGATCCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Qy	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Db	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Qy	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Qy	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860

Db

2521 GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT 2580

Qy	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Qy	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Qy	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Db	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Qy	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Qy	2821	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Db	2821	TTTTTGGATCACAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Qy	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Qy	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	2941		3000
Qy	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Qу	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Qу	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180
Db	3121	GAGTATTTCATGAAACAAATGAATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180
Qу	3181	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA	3240
Db	3181	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA	3240
Qy	3241	GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA	3300
Db	3241	GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA	3300

```
Qу
        3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
             Db
        3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
        3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
QУ
             3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Db
        3421 AAAA 3424
Qу
            Db
        3421 AAAA 3424
RESULT 6
AED31618
    AED31618 standard; cDNA; 3424 BP.
ID
XX
AC
    AED31618;
XX
DT
    15-DEC-2005 (first entry)
XX
DE
    cDNA (SEQ ID No:2) encoding human phosphatidylinositol 3-kinase (PIK3CA).
XX
KW
    cancer; neoplasm; phosphatidylinositol 3-kinase; PIK3CA; tumor;
KW
    chemotherapy; cytostatic; RNA interference; gene silencing;
KW
    antisense therapy; gene; ss.
XX
    Homo sapiens.
OS
XX
                   Location/Qualifiers
FΗ
    Key
                   13. .3219
FT
    CDS
FT
                   /*tag= a
                   /product= "PIK3CA"
FT
XX
    WO2005091849-A2.
PΝ
XX
PD
    06-OCT-2005.
XX
PF
    18-FEB-2005; 2005WO-US005193.
XX
PR
    02-MAR-2004; 2004US-0548886P.
XX
    (UYJO ) UNIV JOHNS HOPKINS.
PΑ
XX
    Samuels Y, Velculescu V, Kinzler KW, Vogelstein B;
PΙ
XX
    WPI; 2005-713721/73.
DR
DR
    P-PSDB; AED31619.
XX
```

Assessing cancer in a human suspected of having cancer, by determining a PΤ non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase PΤ (PIK3CA) coding sequence in the body sample from a human. PΤ XX PS Claim 1; SEQ ID NO 2; 107pp; English. XX CC The invention relates to a method of assessing cancer in a body sample of CC a human suspected of having cancer. The method comprises determining a CC non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase CC (PIK3CA) coding sequence in the body sample, and identifying the human as likely to have cancer if a non-synonymous, intragenic mutation in PIK3CA CC coding sequence is determined in the body sample. Also described are: (1) CC CC a method of inhibiting progression of a tumor in a human; (2) a method of CC identifying candidate chemotherapeutic agents; (3) a method for delivering an appropriate chemotherapeutic drug to a patient in need; and CC (4) a set of one or more primers for amplifying and/or sequencing PIK3CA, CC CCthe primers selected from forward primers, reverse primers, or sequencing primers, where the forward primers are selected from sequences given as CC CC SEQ ID NOs 6-165, the reverse primers are selected from sequences given CC as SEQ ID NOs 166-325, and the sequencing primers are selected sequences given as SEQ ID NOs 326-485 in the specification. The method of the CC CCinvention is useful for assessing cancer in a body sample of a human CCsuspected of having cancer, inhibiting progression of a tumor in a human, CC identifying candidate chemotherapeutic agents, and delivering an CC appropriate chemotherapeutic drug to a patient in need. This sequence CC encodes human PIK3CA. XX SO Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other; 99.9%; Query Match Score 3422.4; DB 4; Length 3424; Best Local Similarity 99.9%; Matches 3423; Conservative 0; Mismatches 1; Indels 0; 0; Gaps 1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60 Qу 1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60 Db 61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120 Qу Db 61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120 Qу 121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAAATAC 180 121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180 Db 181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240 Qу Db 181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240

961 TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA 1020

Db	961		:0
Qy	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT 108	, O
Db	1021		, O
Qу	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA 114	: 0
Db	1081		: 0
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT 120	0
Db	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT 120	0
Qу	1201	CCTCGTGCTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA 126	0
Db	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA 126	0
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA 132	:0
Db	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA 132	:0
Qу	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG 138	0
Db	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG 138	0
Qу	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG 144	: 0
Db	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG 144	: 0
Qу	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC 150	0
Db	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC 150	0
Qу	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA 156	0
Db	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA 156	0
Qy	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA 162	0
Db	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA 162	0
Qу	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC 168	0
Db	1621	CGAGATCCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC 168	0
Qу	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	: 0

Db

2401 AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT 2460

Qy	2461	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2520
Db	2461	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2520
Qy	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Db	2521		2580
Qy	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Qy	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Qy	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Db	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Qy	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Qy	2821	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Db	2821	TTTTTGGATCACAAGAAGAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Qy	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Qу	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Qу	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Qy	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Qy	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180
Db	3121		3180

```
Qу
       3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
           Db
       3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
QУ
           3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Db
Qу
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
           Db
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Qу
           Db
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
       3421 AAAA 3424
Qу
           Db
       3421 AAAA 3424
RESULT 7
AEG93388
ID
    AEG93388 standard; cDNA; 3424 BP.
XX
AC
    AEG93388;
XX
    11-JUN-2007 (revised)
DT
    01-JUN-2006 (first entry)
DT
XX
    Human tumor cell cDNA SEO ID NO:884.
DE
XX
    Gene expression; tumor; ss.
KW
XX
OS
    Homo sapiens.
XX
PN
    W02006036025-A1.
XX
PD
    06-APR-2006.
XX
    30-SEP-2005; 2005WO-JP018574.
PF
XX
    30-SEP-2004; 2004JP-00286259.
PR
    28-FEB-2005; 2005JP-00054475.
PR
    28-FEB-2005; 2005JP-00054866.
PR
XX
PA
    (EISA ) EISAI CO LTD.
XX
```

Owa T, Yokoi A, Ozawa Y, Kawai T, Ushijima R;

PΙ

```
XX
    WPI; 2006-293404/30.
DR
    PC:NCBI; qi472990.
DR
    PC_ENCPRO:NCBI; gi472991.
DR
XX
    Evaluating sensitivity of a tumor cell to a sulfonamide-containing
PΤ
PT
    compound, comprises comparing the expression of specific genes in tumor
    cells before and after administration of the compound.
PT
XX
PS
    Claim 1; SEQ ID NO 884; 1405pp; Japanese.
XX
CC
    The invention relates to a method of evaluating the sensitivity of a
    tumor cell to a sulfonamide-containing compound, by comparing the
CC
    expression level of genes in tumor cells obtained from cancer patients
CC
    before and after administration of the sulfonamide-containing compound
CC
    and determining the tumor cell to be sensitive to the sulfonamide-
CC
CC
    containing compound, when the expression amount of genes in the cell is
CC
    increased compared with the expression amount before administration
CC
    and/or when the expression amount of one or more genes is decreased
CC
    compared with the expression amount before administration. The invention
CC
    also relates to an assay reagent of RNA comprising an oligonucleotide
CC
    complementary to an RNA which is the transcription product of a gene, and
CC
    an immunoassay reagent containing the antibody with respect to a protein
CC
    which is a translation product of the gene. The expression level of the
    gene, which is the RNA transcription product, is measured using a DNA
CC
    microarray or by quantitative PCR. The expression level of protein, which
CC
CC
    is a translation product of the gene, is measured by an immunochemical
    method such as enzyme linked immunosorbent assay (ELISA),
CC
CC
    radioimmunoassay (RIA) or Western blotting. The method enables evaluation
    of the sensitivity of a tumor cell to a sulfonamide-containing compound.
CC
CC
    This sequence represents human tumor cell cDNA used in the scope of the
CC
    invention.
CC
    Revised record issued on 11-JUN-2007: Enhanced with precomputed
CC
CC
    information from BOND.
XX
SO
    Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;
 Query Match
                         99.9%;
                                Score 3422.4; DB 4; Length 3424;
 Best Local Similarity
                         99.9%;
 Matches 3423; Conservative
                              0; Mismatches
                                                 1;
                                                     Indels
                                                              0;
                                                                  Gaps
                                                                          0;
           1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
Qу
             1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
Db
          61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
             Db
          61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
```

Qy	121	CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC	180
Db	121	CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC	180
Qy	181	CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA	240
Db	181	CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA	240
Qy	241	GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA	300
Db	241	GCAGAAAGGGAAGATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA	300
Qy	301	CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA	360
Db	301	CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA	360
Qy	361	ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA	420
Db	361	ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA	420
Qy	421	CAGGACTTCCGAAGAAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT	480
Db	421	CAGGACTTCCGAAGAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT	480
Qy	481	AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG	540
Db	481	AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG	540
Qy	541	CTGCCAAAGCACATATATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA	600
Db	541	CTGCCAAAGCACATATATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA	600
Qy	601	ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTG	660
Db	601	ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTG	660
Qy	661	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTAGAAGTATGTTGCTATCATCT	720
Db	661	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTAGAAGTATGTTGCTATCATCT	720
Qy	721	GAACAATTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGA	780
Db	721	GAACAATTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGA	780
Qy			010
$\Sigma \lambda$	781	TGTGATGAATACTTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGT	040

1501 AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA 1560

Qу

Db

Db	1561		1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621		1680
Qу	1681		1740
Db	1681		1740
Qy	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1741		1800
Qy	1801		1860
Db	1801		1860
Qy	1861	CGGTGCTTGGAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	1861	CGGTGCTTGGAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Qy	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Db	1921		1980
Qy	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Qy	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Db	2041		2100
Qy	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Db	2101		2160
Qy	2161	GACATTCTCAAACAGGAGGAGGAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Db	2161	GACATTCTCAAACAGGAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Qy	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Db	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Qy	2281	CCTGCTCATCAACTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAA	2340

Db

3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060

```
3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Qу
           3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Db
       3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Qу
           3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Db
       3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Qу
           3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Db
Qу
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
           3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Db
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
QУ
           Db
       3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Qy
           Db
       3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
Qу
       3421 AAAA 3424
           3421 AAAA 3424
Db
RESULT 8
AAQ51156
   AAQ51156 standard; cDNA; 3412 BP.
ID
XX
AC
   AAQ51156;
XX
DT
    25-MAR-2003
              (revised)
    12-APR-1994
DT
              (first entry)
XX
DE
    Human p110 cDNA.
XX
    Phosphoinositide kinase; PI; p85 subunit; screening; agonist; antagonist;
KW
    cell proliferation; inhibition; prophylaxis; therapy; platelets;
KW
    neutorphil activity; 3-phosphorylated phosphoinositides; ds.
KW
XX
    Homo sapiens.
OS
XX
FH
                Location/Qualifiers
   Key
    CDS
                 1. .3207
FΤ
```

```
FΤ
                    /*tag=
FT
                    /note= "PI3- kinase p110"
XX
PΝ
    WO9321328-A1.
XX
PD
    28-OCT-1993.
XX
PF
    13-APR-1993;
                  93WO-GB000761.
XX
PR
    13-APR-1992; 92GB-00008135.
XX
PA
     (LUDW-) LUDWIG INST CANCER RES.
XX
PΙ
    Hiles ID, Fry MJ, Dhand R, Waterfield MD, Parker PJ, Otsu M;
PΙ
    Panayotou G, Volinia S, Gout I;
XX
    WPI; 1993-351738/44.
DR
DR
    P-PSDB; AAR43342.
XX
PΤ
    Recombinant polypeptide(s) - with phosphoinositide-3 kinase activity,
    useful for controlling cell proliferation.
PΤ
XX
PS
    Claim 7; Fig 16; 146pp; English.
XX
CC
    Southern blot analysis was performed using a bovine cDNA probe contq. a
    fragment of a PI3-kinase-encoding sequence and human cDNA isolated from a
CC
CC
    cDNA library constructed from mRNA isolated from the human cell line
CC
    KG1a. Positive clones were sequenced to give the human PI3 kinase p110
CC
    sequence shown. This sequence has 95 percent homology with the bovine
    sequence. The domain encoding residues 19- 100 of human p110 is
CC
CC
    sufficient to encode the kinase which will associate with the p85 kinase
CC
    subunit. The gene may be used to provide a protein with PI3 kinase
CC
    activity, and is useful for screening for (ant)agonists of PI3 kinase
    activity which could be useful for stimulation or inhibition of cell
CC
CC
    proliferation and hence prophylaxis or therapy. Platelet or neutrophil
CC
    activity or blood glucose levels can be controlled using the kinase. See
CC
    also AAQ51155 and AAQ57522-3. (Updated on 25-MAR-2003 to correct PN
CC
    field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
SO
    Sequence 3412 BP; 1128 A; 616 C; 706 G; 962 T; 0 U; 0 Other;
 Query Match
                         99.6%;
                                 Score 3410.4; DB 1; Length 3412;
 Best Local Similarity
                         99.9%;
 Matches 3411; Conservative 0; Mismatches
                                                 1;
                                                     Indels
                                                                           0;
                                                               0;
                                                                   Gaps
          13 ATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATGCCCCCAAGAATC 72
Qу
             Db
           1 ATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATGCCCCCAAGAATC 60
```

Db	781		840
Qу	853	AGGATGCCCAATTTGAAGATGATGGCTAAAGAAAGCCTTTATTCTCAACTGCCAATGGAC	912
Db	841	AGGATGCCCAATTTGAAGATGATGGCTAAAGAAAGCCTTTATTCTCAACTGCCAATGGAC	900
Qу	913	TGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCATATATGAATGGA	972
Db	901	TGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCATATATGAATGGA	960
Qу	973	GAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATAAAAATTCTTTGT	1032
Db	961	GAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATAAAAATTCTTTGT	1020
Qy	1033	GCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTTCGAACAGGTATC	1092
Db	1021	GCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTTCGAACAGGTATC	1080
Qу	1093	TACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTACCTTGTTCCAAT	1152
Db	1081	TACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTACCTTGTTCCAAT	1140
Qу	1153	CCCAGGTGGAATGACTGAATTATGATATACATTCCTGATCTTCCTCGTGCTGCT	1212
Db	1141	CCCAGGTGGAATGAATTATGATATATACATTCCTGATCTTCCTCGTGCTGCT	1200
Qу	1213	CGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAAGAGGAACACTGT	1272
Db	1201	CGACTTTGCCTTTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAAGAGGAACACTGT	1260
Qу	1273	CCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTAGTATCTGGAAAA	1332
Db	1261	CCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTAGTATCTGGAAAA	1320
Qy	1333	ATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTGAACCCTATTGGT	1392
Db	1321	ATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTGAACCCTATTGGT	1380
Qу	1393	GTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAGTTTGACTGGTTC	1452
Db	1381	GTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTTGGAGTTTGACTGGTTC	1440
Qу	1453	AGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCCAATTGGTCTGTA	1512
Db	1441	AGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCCAATTGGTCTGTA	1500
Qу	1513	TCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGACTAGCTAG	1572

Db

2233 CGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAACCCTGCTCATCAA 2292

Qy	2293	CTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAAAGGCCACTGTGG	2352
Db	2281	CTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAAAGGCCACTGTGG	2340
Qy	2353	TTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAACAATGAGATCATC	2412
Db	2341		2400
Qy	2413	TTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATTATTCGTATTATG	2472
Db	2401		2460
Qy	2473	GAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTATGGTTGTCTGTC	2532
Db	2461	GAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTATGGTTGTCA	2520
Qy	2533	ATCGGTGACTGTGGGGACTTATTGAGGTGGTGCGAAATTCTCACACTATTATGCAAATT	2592
Db	2521	ATCGGTGACTGTGGGGACTTATTGAGGTGGTGCGAAATTCTCACACTATTATGCAAATT	2580
Qy	2593	CAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACACTACATCAGTGG	2652
Db	2581	CAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACACTACATCAGTGG	2640
Qy	2653	CTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTGTTTACACGTTCA	2712
Db	2641	CTCAAAGACAAGGAGAAATATATGATGCAGCCATTGACCTGTTTACACGTTCA	2700
Qy	2713	TGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGTCACAATAGTAAC	2772
Db	2701	TGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGTCACAATAGTAAC	2760
Qy	2773	ATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACACTTTTTGGATCAC	2832
Db	2761	ATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACACTTTTTGGATCAC	2820
QУ	2833	AAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTGACACAGGATTTC	2892
Db	2821	AAGAAGAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTGACACAGGATTTC	2880
Qy	2893	TTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAATTTGAGAGGTTT	2952
Db	2881	TTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAATTTGAGAGGTTT	2940
Qy	2953	CAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAATCTCTTCATAAAT	3012
Db	2941	CAGGAGATGTTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAATCTCTTCATAAAT	3000

```
Qу
       3013 CTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTTGATGACATTGCA 3072
           3001 CTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTTGATGACATTGCA 3060
Db
       3073 TACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATG 3132
Qу
           3061 TACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATG 3120
Db
Qy
       3133 AAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGATTGGATCTTCCAC 3192
           Db
       3121 AAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGATTGGATCTTCCAC 3180
       3193 ACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAAGCTCACTCTGGA 3252
Qу
           3181 ACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAAGCTCACTCTGGA 3240
Db
       3253 TTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCATAGGAATTGCAC 3312
Qу
           Db
       3241 TTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCATAGGAATTGCAC 3300
       3313 AATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACTATATAATTTAAA 3372
Qу
           Db
       3301 AATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACTATATAATTTAAA 3360
       3373 TAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTCAAAA 3424
Qу
           3361 TAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTCAAAA 3412
Db
RESULT 9
AED31617
   AED31617 standard; cDNA; 3412 BP.
ID
XX
AC
   AED31617;
XX
   15-DEC-2005 (first entry)
DT
XX
DE
   cDNA (SEQ ID No:1) encoding human phosphatidylinositol 3-kinase (PIK3CA).
XX
KW
    cancer; neoplasm; phosphatidylinositol 3-kinase; PIK3CA; tumor;
   chemotherapy; cytostatic; RNA interference; gene silencing;
ΚW
ΚW
    antisense therapy; gene; ss.
XX
   Homo sapiens.
OS
XX
                Location/Qualifiers
FΗ
   Key
   CDS
FT
                1. .3207
FT
                /*tag= a
FΤ
                /product= "PIK3CA"
```

```
XX
     WO2005091849-A2.
PΝ
XX
     06-OCT-2005.
PD
XX
PF
     18-FEB-2005; 2005WO-US005193.
XX
     02-MAR-2004; 2004US-0548886P.
PR
XX
     (UYJO ) UNIV JOHNS HOPKINS.
PA
XX
PΙ
     Samuels Y, Velculescu V, Kinzler KW, Vogelstein B;
XX
     WPI; 2005-713721/73.
DR
     P-PSDB; AED31619.
DR
XX
PT
     Assessing cancer in a human suspected of having cancer, by determining a
     non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase
PΤ
PΤ
     (PIK3CA) coding sequence in the body sample from a human.
XX
PS
     Disclosure; SEQ ID NO 1; 107pp; English.
XX
CC
     The invention relates to a method of assessing cancer in a body sample of
CC
     a human suspected of having cancer. The method comprises determining a
     non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase
CC
CC
     (PIK3CA) coding sequence in the body sample, and identifying the human as
CC
     likely to have cancer if a non-synonymous, intragenic mutation in PIK3CA
CC
     coding sequence is determined in the body sample. Also described are: (1)
CC
     a method of inhibiting progression of a tumor in a human; (2) a method of
     identifying candidate chemotherapeutic agents; (3) a method for
CC
CC
     delivering an appropriate chemotherapeutic drug to a patient in need; and
CC
     (4) a set of one or more primers for amplifying and/or sequencing PIK3CA,
CC
     the primers selected from forward primers, reverse primers, or sequencing
     primers, where the forward primers are selected from sequences given as
CC
CC
     SEQ ID NOs 6-165, the reverse primers are selected from sequences given
CC
     as SEQ ID NOs 166-325, and the sequencing primers are selected sequences
CC
     given as SEQ ID NOs 326-485 in the specification. The method of the
CC
     invention is useful for assessing cancer in a body sample of a human
CC
     suspected of having cancer, inhibiting progression of a tumor in a human,
CC
     identifying candidate chemotherapeutic agents, and delivering an
CC
     appropriate chemotherapeutic drug to a patient in need. This sequence
     encodes human PIK3CA.
CC
XX
SQ
     Sequence 3412 BP; 1128 A; 616 C; 706 G; 962 T; 0 U; 0 Other;
 Query Match
                          99.6%;
                                 Score 3410.4; DB 4; Length 3412;
 Best Local Similarity
                          99.9%;
 Matches 3411; Conservative
                               0; Mismatches
                                                   1;
                                                       Indels
                                                                 0;
                                                                     Gaps
                                                                              0;
```

733 CTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGATGTGATGAATAC 792

Db	721		780
Qу	793	TTCCTAGAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGTATAATGCTTGGG	852
Db	781	TTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGTATAATGCTTGGG	840
Qу	853	AGGATGCCCAATTTGAAGATGATGGCTAAAGAAAGCCTTTATTCTCAACTGCCAATGGAC	912
Db	841	AGGATGCCCAATTTGAAGATGATGGCTAAAGAAAGCCTTTATTCTCAACTGCCAATGGAC	900
Qу	913	TGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCATATATGAATGGA	972
Db	901	TGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCATATATGAATGGA	960
Qу	973	GAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATAAAAATTCTTTGT	1032
Db	961	GAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATAAAAATTCTTTGT	1020
Qу	1033	GCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTTCGAACAGGTATC	1092
Db	1021	GCAACCTACGTGAATATTCGAGACATTGACAAGATTTATGTTCGAACAGGTATC	1080
Qу	1093	TACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTACCTTGTTCCAAT	1152
Db	1081	TACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTACCTTGTTCCAAT	1140
Qу	1153	CCCAGGTGGAATGACTTATGATATACATTCCTGATCTTCCTCGTGCTGCT	1212
Db	1141	CCCAGGTGGAATGACTTATGATATACATTCCTGATCTTCCTCGTGCTGCT	1200
Qу	1213	CGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAAGAGGAACACTGT	1272
Db	1201	CGACTTTGCCTTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAAGAGGAACACTGT	1260
Qу	1273	CCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTAGTATCTGGAAAA	1332
Db	1261	CCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTAGTATCTGGAAAA	1320
Qу	1333	ATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTGAACCCTATTGGT	1392
Db	1321	ATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTGAACCCTATTGGT	1380
Qу	1393	GTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAGTTTGACTGGTTC	1452
Db	1381	GTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTTGACTGGTTC	1440
Qy	1453	AGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCCAATTGGTCTGTA	1512

Db

2173 CAGGAGAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTTGAGCAAATGAGG 2232

Qy	2233	CGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAACCCTGCTCATCAA	2292
Db	2221	CGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAACCCTGCTCATCAA	2280
Qy	2293	CTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAAAGGCCACTGTGG	2352
Db	2281	CTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAAAGGCCACTGTGG	2340
Qy	2353	TTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAACAATGAGATCATC	2412
Db	2341		2400
Qy	2413	TTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATTATTCGTATTATG	2472
Db	2401		2460
Qy	2473	GAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTATGGTTGTCTGTC	2532
Db	2461	GAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTATGGTTGTCA	2520
Qy	2533	ATCGGTGACTGTGGGGACTTATTGAGGTGGTGCGAAATTCTCACACTATTATGCAAATT	2592
Db	2521	ATCGGTGACTGTGGGGACTTATTGAGGTGGTGCGAAATTCTCACACTATTATGCAAATT	2580
Qy	2593	CAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACACTACATCAGTGG	2652
Db	2581	CAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACACTACATCAGTGG	2640
Qy	2653	CTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTGTTTACACGTTCA	2712
Db	2641	CTCAAAGACAAGGAGAAATATATGATGCAGCCATTGACCTGTTTACACGTTCA	2700
Qy	2713	TGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGTCACAATAGTAAC	2772
Db	2701	TGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGTCACAATAGTAAC	2760
QУ	2773	ATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACACTTTTTGGATCAC	2832
Db	2761	ATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACACTTTTTGGATCAC	2820
Qy	2833	AAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTGACACAGGATTTC	2892
Db	2821	AAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTGACACAGGATTTC	2880
Qy	2893	TTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAATTTGAGAGGTTT	2952
Db	2881	TTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAATTTGAGAGGTTT	2940

```
Qу
      2953 CAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAATCTCTTCATAAAT 3012
          Db
      2941 CAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAATCTCTTCATAAAT 3000
      3013 CTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTTGATGACATTGCA 3072
Qу
          3001 CTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTTGATGACATTGCA 3060
Db
Qy
      3073 TACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATG 3132
          Db
      3061 TACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATG 3120
      3133 AAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGATCTTCCAC 3192
Qу
          3121 AAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGATTTGCATCTTCCAC 3180
Db
      3193 ACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAAGCTCACTCTGGA 3252
Qу
          3181 ACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAAGCTCACTCTGGA 3240
Db
      3253 TTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCATAGGAATTGCAC 3312
Qу
          Db
      3241 TTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCATAGGAATTGCAC 3300
      3313 AATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACTATATAATTTAAA 3372
Qу
          3301 AATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACTATATAATTTAAA 3360
Db
      3373 TAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTCAAAA 3424
QУ
          3361 TAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTCAAAA 3412
Db
```

```
ADU05935
     ADU05935 standard; DNA; 3423 BP.
ID
XX
АC
     ADU05935;
XX
DT
     27-JAN-2005 (first entry)
XX
DE
     Novel bronchial cancer-associated human gene SeqID157.
XX
     bronchial cancer; cytostatic; tumour-associated protein;
ΚW
     cancer detection; metastasis; tumour; gene; ds; human.
KW
XX
OS
     Homo sapiens.
XX
```

RESULT 10

PN

DE10316701-A1.

```
XX
PD
    04 - NOV - 2004.
XX
    09-APR-2003; 2003DE-01016701.
PF
XX
PR
    09-APR-2003; 2003DE-01016701.
XX
    (HINZ/) HINZMANN B.
PA
PA
     (HERM/) HERMANN K.
PA
     (CAST/) HEIDEN CASTANOS-VELEZ E.
XX
PΙ
    Mennerich D, Bruemmendorf T, Heiden E, Hermann K, Kinnemann H;
PΙ
    Li X, Roepcke S, Staub E, Hinzmann B, Rosenthal A, Pilarsky C;
XX
    WPI; 2004-786403/78.
DR
    P-PSDB; ADU06422.
DR
XX
    New nucleic acid, and derived proteins, useful for diagnosis of bronchial
PΤ
PΤ
    cancer and in screening for therapeutic and diagnostic agents.
XX
PS
    Claim 1; SEQ ID NO 157; 1381pp; German.
XX
CC
    This invention relates to a novel isolated nucleic acid associated with
CC
    bronchial cancer comprising 489 defined sequences given in the
    specification. The invention may be useful for the production of
CC
    compounds with a cytostatic activity through the inhibition of expression
CC
CC
    or activity of tumour-associated proteins. The novel DNA sequences and
CC
    the proteins/peptides encoded by them are used for detecting bronchial
CC
    cancer or determining the risk of developing it and to screen for
    specific binding partners of the DNA or protein sequences, where the
CC
CC
    binding partners are potentially useful as agents for treating or
CC
    diagnosing bronchial cancer. The DNA or protein sequences can also be
CC
    used for prognosis, detection of metastases and for secondary treatment
    (of tumours that have been stabilised or are no longer detectable).
CC
CC
    Detecting abnormal expression of the DNA sequences provides early
CC
    diagnosis of bronchial cancers. The present sequence is that of a novel
CC
    bronchial cancer-associated human gene sequence of the invention.
XX
SQ
    Sequence 3423 BP; 1134 A; 618 C; 709 G; 962 T; 0 U; 0 Other;
 Query Match
                         99.6%; Score 3410.4; DB 3; Length 3423;
 Best Local Similarity
                         99.9%;
 Matches 3422; Conservative 0; Mismatches
                                                 1;
                                                     Indels
                                                                   Gaps
                                                                           1;
Qу
           1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60
             1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Db
          61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
```



Qy	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621		1680
Qy	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Db	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Qу	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Qу	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Db	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Qу	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Qу	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Db	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Qу	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTTGGCATTTAAAATCTGAGATGCAC	2040
Qу	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Db	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Qу	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACT	2160
Db	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Qу	2161	GACATTCTCAAACAGGAGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Db	2161	GACATTCTCAAACAGGAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Qy	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Db	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280

3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060

```
3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060
Db
      3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Qу
          3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Db
      3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Qу
          Db
       3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
      3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
QУ
          3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAGATAACTGAGAAAATGAAA 3240
Db
       3241 GCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGCA 3300
Qу
          3241 GCTCACTCTGGATTCCACACTGCACTG-TAATAACTCTCAGCAGGCAAAGACCGATTGCA 3299
Db
      3301 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3360
Qу
          Db
       3300 TAGGAATTGCACAATCCATGAACAGCATTAGATTTACAGCAAGAACAGAAATAAAATACT 3359
      3361 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3420
QУ
          Db
       3360 ATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATTTC 3419
      3421 AAAA 3424
Qу
          3420 AAAA 3423
Db
RESULT 11
ARC02473
   ARC02473 standard; DNA; 3426 BP.
ID
XX
AC
   ARC02473;
XX
DT
   10-JUL-2008 (first entry)
XX
   DNA fragments of a human Tox gene, 46524.
DE
XX
KW
   DNA microarray; gene expression; drug screening; ds; Tox.
XX
OS
   Homo sapiens.
XX
   US2007072175-A1.
PΝ
XX
   29-MAR-2007.
PD
```

```
XX
PF
     15-MAY-2006; 2006US-00433832.
XX
     13-MAY-2005; 2005US-0680473P.
PR
     13-MAY-2005; 2005US-0680544P.
PR
XX
PA
     (BIOJ ) BIOGEN IDEC MA INC.
XX
PΙ
     Cooper MT,
                 Kinch D, Rosenberg M, Subramaniam SS,
                                                          Szak ST,
PΙ
     Bandaru R,
                 Derbel M;
XX
     WPI; 2007-432796/41.
DR
XX
PΤ
     New nucleotide array comprises polynucleotide probes complementary to, or
     fragments of, Cynomolgus monkey genes, useful for detecting changes in
PT
     gene expression upon administration of a therapeutic agent.
PT
XX
ΡS
     Claim 18; SEQ ID NO 46524; 33pp; English.
XX
CC
     The new invention relates to a nucleotide array for detecting changes in
     gene expression upon administration of a therapeutic agent. The
CC
CC
     microarray has polynucleotide probes complementary to, or fragments of,
CC
     Cynomolgus monkey genes, where each polynucleotide probe is immobilized
CC
     to a discrete and known spot on a solid support. The polynucleotide
     probes are complementary to, or fragments of, any portion of an ortholog
CC
     of a human gene, preferably a Tox gene. The probes are any of SEQ ID NO.
CC
CC
     8882-9186. The probes are also complementary to, or fragments of, any
     portion of any of SEQ ID NO. 1-8881 or 9187-18598. The nucleotide array
CC
CC
     has at least one probe complementary to, or a fragment of, any portion of
     any human gene, where the probe from a human gene is any of SEQ ID NO.
CC
     43226-48714, or is complementary to, or a fragment of, any portion of any
CC
CC
     of SEQ ID NO. 43450-48714. The array has at least one probe complementary
CC
     to, or a fragment of, any portion of any Rhesus monkey gene, where the
     probe from a Rhesus monkey gene is any of SEQ ID NO. 35841-36074, or is
CC
     complementary to, or a fragment of, any portion of any of SEQ ID NO.
CC
CC
     18599-35840 or 36075-43225. It also has at least one probe complementary
CC
     to, or a fragment of, any portion of a Rhesus monkey gene and at least
CC
     one probe complementary to, or a fragment of, any portion of any human
CC
     gene. The nucleotide array is useful for detecting changes in gene
CC
     expression upon administration of a therapeutic agent. It can be used for
     characterizing the actions, targets, and toxicities of therapeutic agents
CC
     in primates, e.g. a human, a Cynomolgus monkey, or a Rhesus monkey. This
CC
CC
     sequence is a DNA fragment of a human Tox gene.
XX
SO
     Sequence 3426 BP; 1138 A; 623 C; 703 G; 962 T; 0 U; 0 Other;
 Query Match
                          97.5%;
                                  Score 3338; DB 6; Length 3426;
  Best Local Similarity
                          98.8%;
 Matches 3384; Conservative
                                 0; Mismatches
                                                  40;
                                                       Indels
                                                                  2;
                                                                              2;
                                                                      Gaps
```



Db

Qу

1381 AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG 1440

1441 TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC 1500

Db	1441		1500
Qy	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1501		1560
Qy	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1561		1620
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1621		1680
Qy	1681		1740
Db	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Qy	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Qy	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Db	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Qy	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Qy	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Db	1921		1980
Qy	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Qy	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Db	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Qy	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Db	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Qy	2161	GACATTCTCAAACAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220

Db

2881 ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA 2940

```
2941 TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT 3000
Qу
          2941 TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT 3000
Db
      3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060
QУ
          3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060
Db
      3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Qу
          3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Db
Qу
      3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
          3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Db
      3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTG-AAAGATAACTGAGAAAATGAA 3239
Qу
          3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGATAACTGAGAAAATGAA 3240
Db
      3240 AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC 3299
Qу
          Db
      3241 AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC 3300
Qу
      3301 ATAGGAATTGCACAATCCATGAACAGCATTAGAATTTACAGCAAGAACAGAAATAAAATA 3360
Db
      3359 CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT 3418
Qу
          3361 CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT 3420
Db
      3419 TCAAAA 3424
QУ
          3421 TCAAAA 3426
Db
RESULT 12
AEK54940
   AEK54940 standard; DNA; 3724 BP.
ID
XX
AC
   AEK54940;
XX
   11-JUN-2007
             (revised)
DT
   16-NOV-2006
DT
             (first entry)
XX
```

Human PIK3CA DNA, SEQ ID NO:7.

DE XX

```
phosphoinositide-3-kinase, catalytic, alpha; PIK3CA; genetic marker;
ΚW
     screening; adenocarcinoma; neoplasm; cytostatic; ds.
KW
XX
OS
     Homo sapiens.
XX
     WO2006094149-A2.
PΝ
XX
     08-SEP-2006.
PD
XX
PF
     01-MAR-2006; 2006WO-US007493.
XX
     01-MAR-2005; 2005US-0657841P.
PR
XX
     (EXAC-) EXACT SCI CORP.
PA
XX
PΙ
     Shuber AP;
XX
DR
     WPI; 2006-680485/70.
     REFSEQ; NM_006218.
DR
DR
     PC:NCBI; gi54792081.
     PC ENCPRO: NCBI; qi54792082.
DR
XX
```

PT Screening for adenoma in a subject, comprises testing a sample for the PT presence of each of a panel of genetic markers, where the panel is more than 60% informative for adenoma.

Disclosure; SEQ ID NO 7; 79pp; English.

XX PS

XX CC

CC

CC

CC

CC

CC CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC CC

CC

CC CC The invention relates to a method for screening a subject for the presence of adenoma. The method comprises interrogating a sample from the subject for each of a panel of genetic markers, where the panel is more than 60% informative for adenoma, and where the presence of one or more of the markers is indicative of adenoma. Also described are: (1) a method of detecting indicia of adenoma, by assaying a sample from a subject for the presence of one or more genetic abnormalities from a group of genetic abnormalities that is more than 60% informative for adenoma; (2) a method of detecting adenoma in a subject, by performing an assay on a sample from the subject that is more than 60% informative for adenoma; and (3) a kit comprising a group of oligonucleotides, where each oligonucleotide is adapted for interrogating a genetic locus for the presence of a marker from a panel that is at least 60% informative for adenoma. The methods and kit of the invention are useful for screening for adenoma in a subject. The adenoma is especially a colonic and/or invasive adenoma. The methods can detect adenoma at an early stage with a high level of confidence, increasing the chances of successful treatment. This sequence represents a human DNA sequence that can be used as a genetic marker in the method of the invention.

Revised record issued on 11-JUN-2007: Enhanced with precomputed

```
CC
   information from BOND.
XX
   Sequence 3724 BP; 1242 A; 684 C; 763 G; 1035 T; 0 U; 0 Other;
SO
                   97.5%;
 Query Match
                         Score 3338; DB 4;
                                       Length 3724;
 Best Local Similarity
                  98.8%;
 Matches 3384; Conservative
                        0;
                                     40;
                           Mismatches
                                         Indels
                                                 2;
                                                          2;
                                                    Gaps
         1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Qу
          Db
       146 AGAATCAGAACAATGCCTCCACGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 205
        61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
          206 CCCCCAAGAATCCTAGTAGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 265
Db
       121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Qу
          266 CTCCGTGAGGCTACATTAATAACCATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 325
Db
       181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Qу
          Db
       326 CCCCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACTCAAGAA 385
       241 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA 300
Qу
          386 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGACCTTCGGCTTTTTCAA 445
Db
       301 CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 360
Qу
          446 CCCTTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 505
Db
       361 ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA 420
Qу
          506 ATTGGTTTTGCTATCGGCATGCCAGTGTGTGAATTTGATATGGTTAAAGATCCAGAAGTA 565
Db
       421 CAGGACTTCCGAAGAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT 480
QУ
          Db
       566 CAGGACTTCCGAAGAATATTCTGAACGTTTGTAAAGAAGCTGTGGATCTTAGGGACCTC 625
       481 AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG 540
Qу
          626 AATTCACCTCATAGTAGAGCAATGTATGTCTATCCTCCAAATGTAGAATCTTCACCAGAA 685
Db
       541 CTGCCAAAGCACATATATAATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA 600
Qу
           686 TTGCCAAAGCACATATATAATAAATTAGATAAAGGGCAAATAATAGTGGTGATCTGGGTA 745
Db
       601 ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTG 660
Qу
```

Db	746		805
Qу	661	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTAGAAGTATGTTGCTATCATCT	720
Db	806	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTCGAAGTATGTTGCTATCCTCT	865
Qy	721	GAACAATTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGA	780
Db	866	GAACAACTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTATATTTTAAAAGTGTGTGGA	925
Qy	781	TGTGATGAATACTTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGT	840
Db	926	TGTGATGAATACTTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGT	985
Qy	841	ATAATGCTTGGGAGGATGCCCAATTTGAAGATGATGGCTAAAGAAAG	900
Db	986	ATAATGCTTGGGAGGATGCCCAATTTGATGTTGATGGCTAAAGAAAG	1045
Qу	901	CTGCCAATGGACTGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCA	960
Db	1046	CTGCCAATGGACTGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCA	1105
Qу	961	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA	1020
Db	1106	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGTGCACTCAGAATA	1165
Qу	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Db	1166	AAAATTCTTTGTGCAACCTACGTGAATGTAAATATTCGAGACATTGATAAGATCTATGTT	1225
QУ	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Db	1226	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1285
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1286	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1345
QУ	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1346	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1405
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db	1406	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1465
Qу	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380

Qy	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Db	2246	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACT	2305
Qy	2161	GACATTCTCAAACAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Db	2306	GACATTCTCAAACAGGAGAAGAAGGATGAAACACAAAAAGGTACAGATGAAGTTTTTAGTT	2365
Qy	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Db	2366	GAGCAAATGAGGCGACCAGATTTCATGGATGCTCTACAGGGCTTTCTGTCTCCTCTAAAC	2425
Qy	2281	CCTGCTCATCAACTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAA	2340
Db	2426	CCTGCTCATCAACTAGGAAACCTCAGGCTTGAAGAGTGTCGAATTATGTCCTCTGCAAAA	2485
Qy	2341	AGGCCACTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAAC	2400
Db	2486	AGGCCACTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAAC	2545
Qy	2401	AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT	2460
Db	2546	AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT	2605
Qy	2461	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2520
Db	2606	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2665
Qy	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Db	2666	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2725
Qy	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2726	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2785
Qу	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2786	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2845
Qy	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Db	2846	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2905
Qy	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2906	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2965

```
Qу
      2821 TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG 2880
         Db
      2966 TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG 3025
      2881 ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA 2940
Qу
         3026 ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA 3085
Db
      2941 TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT 3000
Qу
         Db
      3086 TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT 3145
      3001 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3060
Qу
         3146 CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT 3205
Db
      3061 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3120
Qу
         3206 GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG 3265
Db
      3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
Qу
         Db
      3266 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3325
      3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTG-AAAGATAACTGAGAAAATGAA 3239
Qу
         3326 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGATAACTGAGAAAATGAA 3385
Db
      3240 AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC 3299
Qу
         3386 AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC 3445
Db
      Qу
         3446 ATAGGAATTGCACAATCCATGAACAGCATTAGAATTTACAGCAAGAACAGAAATAAAATA 3505
Db
      3359 CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT 3418
QУ
         Db
      3506 CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT 3565
      3419 TCAAAA 3424
Qу
         3566 TCAAAA 3571
Db
```

```
RESULT 13
AER29796
ID AER29796 standard; DNA; 3724 BP.
```

XX

```
AER29796;
AC
XX
DT
     11-JUN-2007
                 (revised)
     22-MAR-2007 (first entry)
DT
XX
DE
    Breast cancer-associated gene SEQ ID NO:97.
XX
     diagnosis; breast tumor; biochip; tumor marker; genetic marker;
KW
     biomarker; DNA detection; RNA detection; ds; PIK3CA.
KW
XX
OS
     Homo sapiens.
XX
PN
     WO2007006911-A2.
XX
     18-JAN-2007.
PD
XX
PF
     05-JUL-2006; 2006WO-FR001593.
XX
PR
     07-JUL-2005; 2005FR-00052087.
XX
PΑ
     (INMR ) BIOMERIEUX SA.
XX
PΙ
     Krause A, Leissner P, Mougin B, Paye M;
XX
DR
    WPI; 2007-138577/14.
     PC:NCBI; qi54792081.
DR
    PC ENCPRO: NCBI; qi54792082.
DR
XX
PT
     In vitro diagnosis of breast cancer comprises extracting biological
     material of biological sample, contacting biological material with
PΤ
     specific reagents of target genes and determining target gene expression.
PΤ
XX
PS
     Example 2; SEQ ID NO 97; 305pp; French.
XX
CC
     The invention describes a method for in vitro diagnosis of breast cancer
CC
     in a patient susceptible to be affected by breast cancer, comprising:
CC
     extracting nucleic acid from a biological sample taken from the patient;
CC
     contacting the nucleic acid with at least 8 hybridization probes for
CC
     detection of target genes chosen from SEQ ID Nos. 1 to 8 or 10 probes for
     detection of target genes chosen from SEQ ID Nos. 1, 2, 4, 6, 13, 14, 26,
CC
     69, 81 and 105; and determining the expression of the target genes. The
CC
     invention also includes: a support, such as a biochip, comprising at
CC
CC
     least 8 or 10 hybridization probes mentioned above; and a diagnosis kit
     for breast cancer comprising the support. The method, biochip and kit are
CC
     useful for the in vitro diagnosis of breast cancer. This sequence is a
CC
CC
     breast cancer-associated gene.
CC
CC
    Revised record issued on 11-JUN-2007: Enhanced with precomputed
CC
     information from BOND.
```

```
XX
SO
   Sequence 3724 BP; 1242 A; 684 C; 763 G; 1035 T; 0 U; 0 Other;
 Query Match
                   97.5%;
                        Score 3338; DB 5;
                                      Length 3724;
 Best Local Similarity
                   98.8%;
                        0;
 Matches 3384; Conservative
                                    40:
                                        Indels
                                                        2;
                           Mismatches
                                               2:
                                                  Gaps
        1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Qу
          Db
       146 AGAATCAGAACAATGCCTCCACGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 205
       61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
Qу
          206 CCCCCAAGAATCCTAGTAGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 265
Db
       121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Qу
          266 CTCCGTGAGGCTACATTAATAACCATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 325
Db
       181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Qу
          Db
       326 CCCCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACTCAAGAA 385
       241 GCAGAAAGGGAAGATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA 300
Qу
          Db
       386 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGACCTTCGGCTTTTTCAA 445
       301 CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 360
Qу
          446 CCCTTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 505
Db
       361 ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA 420
Qу
          506 ATTGGTTTTGCTATCGGCATGCCAGTGTGTGAATTTGATATGGTTAAAGATCCAGAAGTA 565
Db
       421 CAGGACTTCCGAAGAAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT 480
Qу
          Db
       566 CAGGACTTCCGAAGAATATTCTGAACGTTTGTAAAGAAGCTGTGGATCTTAGGGACCTC 625
       481 AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG 540
Qу
          626 AATTCACCTCATAGTAGAGCAATGTATGTCTATCCTCCAAATGTAGAATCTTCACCAGAA 685
Db
       541 CTGCCAAAGCACATATATAATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA 600
Qу
           686 TTGCCAAAGCACATATATAAAATTAGATAAAGGGCAAATAATAGTGGTGATCTGGGTA 745
Db
       601 ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTG 660
QУ
```

Db	746	ATAGTTTCTCCAAATAATGACAAGCAGAAGTATACTCTGAAAATCAACCATGACTGTGTA	805
Qy	661	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTAGAAGTATGTTGCTATCATCT	720
Db	806	CCAGAACAAGTAATTGCTGAAGCAATCAGGAAAAAAACTCGAAGTATGTTGCTATCCTCT	865
Qу	721	GAACAATTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTACATTTTAAAAGTGTGTGGA	780
Db	866	GAACAACTAAAACTCTGTGTTTTAGAATATCAGGGCAAGTATATTTTAAAAGTGTGTGGA	925
Qу	781	TGTGATGAATACTTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGT	840
Db	926	TGTGATGAATACTTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTATATAAGAAGCTGT	985
Qу	841	ATAATGCTTGGGAGGATGCCCAATTTGAAGATGATGGCTAAAGAAAG	900
Db	986	ATAATGCTTGGGAGGATGCCCAATTTGATGTTGATGGCTAAAGAAAG	1045
Qу	901	CTGCCAATGGACTGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCA	960
Db	1046	CTGCCAATGGACTGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCA	1105
Qy	961	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGAGCACTCAGAATA	1020
Db	1106	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGTGCACTCAGAATA	1165
Qу	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Db	1166	AAAATTCTTTGTGCAACCTACGTGAATGTAAATATTCGAGACATTGATAAGATCTATGTT	1225
Qу	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Db	1226	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1285
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1286	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1345
Qу	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1346	CCTCGTGCTGCTCGACTTTGCCTTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1405
Qу	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db		GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	
Qу		GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	
Db	1466	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1525

Qy	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1526	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1585
Qу	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Db	1586		1645
Qy	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1646	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1705
Qy	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1706	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1765
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680
Db	1766		1825
Qy	1681	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1740
Db	1826		1885
Qy	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1886	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1945
Qу	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Db	1946	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	2005
Qy	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	2006	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	2065
Qy	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Db	2066	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	2125
Qy	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	2126		2185
Qу	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Db	2186		2245

Db

Qу

2821 TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG 2880

Db	2966		3025
Qy	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	3026	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	3085
Qу	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	3086	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3145
Qy	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3146	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3205
Qу	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3206	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3265
Qу	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180
Db	3266		3325
Qy	3181	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTG-AAAGATAACTGAGAAAATGAA	3239
Db	3326	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGATAACTGAGAAAATGAA	3385
Qу	3240	AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC	3299
Db	3386	AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC	3445
Qy	3300	ATAGGAATTGCACAATCCATGAACAGCATTAG-ATTTACAGCAAGAACAGAAATAAAATA	3358
Db	3446	ATAGGAATTGCACAATCCATGAACAGCATTAGAATTTACAGCAAGAACAGAAATAAAATA	3505
Qу	3359	CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT	3418
Db	3506	CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT	3565
Qy	3419	TCAAAA 3424	
Db	3566	TCAAAA 3571	

```
RESULT 14
ARV60468
```

ID ARV60468 standard; cDNA; 3724 BP.

XX

AC ARV60468;

XX

```
DT
     24-JUL-2008
                  (first entry)
XX
     Human PIK3CA polynucleotide, SEQ ID 30.
DE
XX
KW
     mutation; dna microarray; prognosis; diagnostic test; therapeutic;
     non-small-cell lung cancer; tumor; cytostatic; ss; gene;
ΚW
     phosphoinositide-3-kinase, catalytic, alpha polypeptide; PIK3CA.
KW
XX
OS
     Homo sapiens.
XX
FH
     Kev
                     Location/Qualifiers
FT
     CDS
                     158. .3364
FT
                     /*tag= a
                     /product
FT
XX
PΝ
     WO2008061213-A2.
XX
PD
     22-MAY-2008.
XX
PF
     15-NOV-2007; 2007WO-US084888.
XX
PR
     16-NOV-2006; 2006US-0866103P.
PR
     10-JUL-2007; 2007US-0948818P.
XX
PA
     (GETH ) GENENTECH INC.
XX
PΙ
     Seshagiri S, Peters B, Kan Z;
XX
     WPI; 2008-G25985/39.
DR
     P-PSDB; ARV60505.
DR
DR
     PC:NCBI; gi54792081.
     PC_ENCPRO:NCBI; gi54792082.
DR
XX
PΤ
     New isolated polynucleotide comprises PRO polynucleotide or fragment
PΤ
     comprising a nucleotide variation, useful for detecting nucleotide
PΤ
     variations for diagnosing and treating tumors.
XX
ΡS
     Claim 2; SEQ ID NO 30; 55pp; English.
XX
     The present invention relates to a novel isolated polynucleotide
CC
     comprising a PRO polynucleotide or its fragment. The PRO polynucleotide
CC
CC
     or its fragment comprises a nucleotide variation at a nucleotide position
     given in the specification. A nucleotide variation refers to a change in
CC
     a nucleotide sequence (e.g., an insertion, deletion, inversion, or
CC
CC
     substitution of one or more nucleotides, such as a single nucleotide
CC
     polymorphism (SNP)) relative to a reference sequence (e.g., a wild type
CC
     sequence). A nucleotide variation may be a somatic mutation or a germline
CC
     polymorphism. The present invention provides: (i) an allele-specific
```

CC

Db

comprising a nucleotide variation at a nucleotide position, or its CC CC complement; (ii) a kit comprising the oligonucleotide and an enzyme; CC (iii) a microarray comprising the oligonucleotide; (iv) a method for CC detecting the absence or presence of the variation at a nucleotide CC position; (v) a method for amplifying a nucleic acid comprising the CC nucleotide variation; (vi) a method for determining the genotype of a CC biological sample (e.g. non-small cell lung carcinoma sample) from a CC mammal; (vii) a method for classifying a tumor in the mammal; and (viii) CC a method for predicting whether a tumor (e.g. non-small cell lung CCcarcinoma) will respond to a therapeutic agent that targets a PRO or a CC PRO polynucleotide, comprises determining whether the tumor comprises a CC variation in a PRO or PRO polynucleotide, where the presence of a CC variation indicates that the tumor will respond to the therapeutic agent. CC The method of detecting the absence or presence of the nucleotide CC variation comprises: (a) contacting the suspected nucleic acid with the CCallele-specific oligonucleotide that is specific for the nucleotide CC variation, under conditions suitable for hybridization of the CC oligonucleotide to the nucleic acid; and (b) detecting the absence or CCpresence of allele-specific hybridization. The method of amplifying the CC nucleic acid comprising the nucleotide variation comprises: (a) CC contacting the nucleic acid with a primer that hybridizes to the nucleic CC acid at 3' of the nucleotide variation; and (b) extending the primer to CC generate an amplification product comprising the nucleotide variation. The isolated polynucleotide is used for detecting nucleotide variations. CC The methods are used for diagnosing and treating tumors. The present CC CC sequence is a human PRO polynucleotide sequence used in the invention. CC CC Revised record issued on 18-JUN-2008: Enhanced with precomputed CCinformation from BOND. XX SQ Sequence 3724 BP; 1242 A; 684 C; 763 G; 1035 T; 0 U; 0 Other; Ouery Match 97.5%; Score 3338; DB 7; Length 3724; Best Local Similarity 98.8%; Matches 3384; Conservative 0; Mismatches 40; Indels 2; Gaps 1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCCATCCACTTGATG 60 Qу Db 146 AGAATCAGAACAATGCCTCCACGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 205 Qу 61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120 Db 206 CCCCCAAGAATCCTAGTAGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 265 121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180 Qу

oligonucleotide that hybridizes to a region of a PRO polynucleotide

266 CTCCGTGAGGCTACATTAATAACCATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 325

Qу

901 CTGCCAATGGACTGTTTTACAATGCCATCTTATTCCAGACGCATTTCCACAGCTACACCA 960

Db	1046		1105
Qy	961		1020
Db	1106	TATATGAATGGAGAAACATCTACAAAATCCCTTTGGGTTATAAATAGTGCACTCAGAATA	1165
Qу	1021	AAAATTCTTTGTGCAACCTACGTGAATCTAAATATTCGAGACATTGACAAGATTTATGTT	1080
Db	1166	AAAATTCTTTGTGCAACCTACGTGAATGTAAATATTCGAGACATTGATAAGATCTATGTT	1225
Qу	1081	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1140
Db	1226	CGAACAGGTATCTACCATGGAGGAGAACCCTTATGTGACAATGTGAACACTCAAAGAGTA	1285
Qу	1141	CCTTGTTCCAATCCCAGGTGGAATGAATGGCTGAATTATGATATACATTCCTGATCTT	1200
Db	1286		1345
Qу	1201	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1260
Db	1346	CCTCGTGCTCGACTTTGCCTTTCCATTTGCTCTGTTAAAGGCCGAAAGGGTGCTAAA	1405
Qy	1261	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1320
Db	1406	GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA	1465
Qy	1321	GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG	1380
Db	1466		1525
Qy	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1526	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1585
Qy	1441		1500
Db	1586	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1645
Qу	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1646	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1705
Qy	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1706	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1765
Qy	1621	CGAGATCCTCTCACTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1680

Db	1766	CGAGATCCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1825
Qy	1681		1740
Db	1826	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1885
Qу	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1886	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1945
Qу	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Db	1946	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	2005
Qy	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	2006	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	2065
Qу	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Db	2066	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	2125
Qу	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	2126	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2185
Qу	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100
Db	2186	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTTGGAGTCCTATTGTCGTGCATGTGGG	2245
Qy	2101	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2160
Db	2246	ATGTATTTGAAGCACCTGAATAGGCAAGTCGAGGCAATGGAAAAGCTCATTAACTTAACT	2305
Qy	2161	GACATTCTCAAACAGGAGGAGGAAGGATGAAACACAAAAGGTACAGATGAAGTTTTTAGTT	2220
Db	2306	GACATTCTCAAACAGGAGAAGAAGGATGAAACACAAAAAGGTACAGATGAAGTTTTTAGTT	2365
Qy	2221	GAGCAAATGAGGCGACCAGATTTCATGGATGCCCTACAGGGCTTGCTGTCTCCTCTAAAC	2280
Db	2366	GAGCAAATGAGGCGACCAGATTTCATGGATGCTCTACAGGGCTTTCTGTCTCCTCTAAAC	2425
Qy	2281	CCTGCTCATCAACTAGGAAACCTCAGGCTTAAAGAGTGTCGAATTATGTCTTCTGCAAAA	2340
Db	2426	CCTGCTCATCAACTAGGAAACCTCAGGCTTGAAGAGTGTCGAATTATGTCCTCTGCAAAA	2485
Qy	2341	AGGCCACTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAAC	2400
Db	2486	AGGCCACTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTCAGAAC	2545

Qy	2401	AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT	2460
Db	2546	AATGAGATCATCTTTAAAAATGGGGATGATTTACGGCAAGATATGCTAACACTTCAAATT	2605
Qy	2461	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2520
Db	2606	ATTCGTATTATGGAAAATATCTGGCAAAATCAAGGTCTTGATCTTCGAATGTTACCTTAT	2665
Qy	2521	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2580
Db	2666	GGTTGTCTGTCAATCGGTGACTGTGTGGGACTTATTGAGGTGGTGCGAAATTCTCACACT	2725
Qу	2581	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2640
Db	2726	ATTATGCAAATTCAGTGCAAAGGCGGCTTGAAAGGTGCACTGCAGTTCAACAGCCACACA	2785
Qу	2641	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2700
Db	2786	CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAGCCATTGACCTG	2845
Qу	2701	TTTACACGTTCATGTGCTGGATACTGTGTAGCTACCTTCATTTTGGGAATTGGAGATCGT	2760
Db	2846		2905
Qy	2761	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC	2820
Db	2906		2965
Db Qy	2906 2821	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	
	2821		2965
Qy	2821 2966	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025
Qy Db	2821 2966 2881	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025 2940
Qy Db Qy	2821 2966 2881	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025 2940 3085
Qy Db Qy Db	2821 2966 2881 3026 2941	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025 2940 3085 3000
Qy Db Qy Db	2821 2966 2881 3026 2941 3086	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025 2940 3085 3000 3145
Qy Db Qy Db Qy Db	2821 2966 2881 3026 2941 3086 3001	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025 2940 3085 3000 3145 3060
Qy Db Qy Db Qy Db	2821 2966 2881 3026 2941 3086 3001 3146	CACAATAGTAACATCATGGTGAAAGACGATGGACAACTGTTTCATATAGATTTTGGACAC TTTTTGGATCACAAGAAGAAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2965 2880 3025 2940 3085 3000 3145 3060 3205

```
Qу
      3121 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3180
          Db
       3266 GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT 3325
      3181 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTG-AAAGATAACTGAGAAAATGAA 3239
QУ
          3326 TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGATAACTGAGAAAATGAA 3385
Db
Qy
      3240 AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC 3299
          Db
       3386 AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC 3445
      Qу
          Db
       3446 ATAGGAATTGCACAATCCATGAACAGCATTAGAATTTACAGCAAGAACAGAAATAAAATA 3505
      3359 CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT 3418
Qу
          3506 CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT 3565
Db
      3419 TCAAAA 3424
Qу
          Db
      3566 TCAAAA 3571
RESULT 15
ARW65283
   ARW65283 standard; cDNA; 3724 BP.
ID
XX
AC
   ARW65283;
XX
   07-AUG-2008 (first entry)
DT
XX
DE
   Human PIK3CA cDNA, SEO ID 53.
XX
   tumor marker; prognosis; diagnostic test; cancer; ss; gene; PIK3CA.
ΚW
XX
OS
   Homo sapiens.
XX
PΝ
   W02008070325-A2.
XX
PD
   12-JUN-2008.
XX
PF
   24-OCT-2007; 2007WO-US082397.
XX
   26-OCT-2006; 2006US-0863106P.
PR
   14-MAY-2007; 2007US-0917814P.
PR
XX
PA
    (GETH ) GENENTECH INC.
```

XX
PI Kan Z, Kenski DM, Peters B, Seshagiri S;
XX
DR WPI; 2008-G69314/42.
DR P-PSDB; ARW65361.
DR PC:NCBI; gi54792081.
DR PC_ENCPRO:NCBI; gi54792082.

XX PT

PT

PT

PT XX PS

XX CC

CC CC

CC

CC

CC CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC CC

CC CC

CC

New polynucleotide, useful for determining the genotype of a sample from a mammal, for classifying a tumor in a mammal or for predicting whether a tumor will respond to a therapeutic agent that targets a PRO polypeptide or polynucleotide.

Claim 2; SEQ ID NO 53; 98pp; English.

The present invention relates to novel isolated polynucleotides. An isolated polynucleotide comprises: (a) a PRO polynucleotide or its fragment that is at least about 10 nucleotides in length or that comprises a nucleotide variation at a nucleotide position given in the specification, or (b) its complement. These variations provide biomarkers for cancer and/or predisposition to tumorigenesis or tumor promotion. The present invention provides: (1) a kit comprising the oligonucleotide and at least one enzyme; (2) a microarray comprising the oligonucleotide; (3) a method for detecting the absence or presence of a nucleotide variation at a nucleotide position given in the specification, which comprises contacting the nucleic acid suspected of comprising the nucleotide variation with an allele-specific oligonucleotide that is specific for the nucleotide variation and detecting the absence or presence of allelespecific hybridization; (4) a method for amplifying a nucleic acid comprising a nucleotide variation at a nucleotide position given in the specification; (5) a method for determining the genotype of a tumor sample from a mammal; (6) a method for classifying a tumor in a mammal by detecting the presence of a variation in a PRO or PRO polynucleotide in a biological sample derived from the mammal; and (7) a method for predicting whether a tumor will respond to a therapeutic agent that targets a PRO or a PRO polynucleotide by determining whether the tumor comprises a variation in a PRO or PRO polynucleotide, where the presence of a variation indicates that the tumor will respond to the therapeutic agent. The method of amplifying a nucleic acid comprising a nucleotide variation comprises: (a) contacting the nucleic acid with a primer that hybridizes to the nucleic acid at a sequence 3' of the nucleotide variation, and (b) extending the primer to generate an amplification product comprising the nucleotide variation. The variations disclosed in the invention are useful in methods and compositions related to cancer diagnosis and therapy. The present sequence is an isolated polynucleotide of the invention.

Revised record issued on 09-JUL-2008 : Enhanced with precomputed infor

```
CC
CC
   Revised record issued on 09-JUL-2008: mation from BOND.
XX
   Sequence 3724 BP; 1242 A; 684 C; 763 G; 1035 T; 0 U; 0 Other;
SQ
 Query Match
                   97.5%;
                         Score 3338; DB 7; Length 3724;
 Best Local Similarity
                   98.8%;
                                     40;
                                                 2;
 Matches 3384; Conservative
                        0; Mismatches
                                         Indels
                                                   Gaps
                                                          2;
         1 AGGATCAGAACAATGCCTCCAAGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 60
Qу
          146 AGAATCAGAACAATGCCTCCACGACCATCATCAGGTGAACTGTGGGGCATCCACTTGATG 205
Db
Qу
        61 CCCCCAAGAATCCTAGTGGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 120
          206 CCCCCAAGAATCCTAGTAGAATGTTTACTACCAAATGGAATGATAGTGACTTTAGAATGC 265
Db
       121 CTCCGTGAGGCTACATTAGTAACTATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 180
Qу
          266 CTCCGTGAGGCTACATTAATAACCATAAAGCATGAACTATTTAAAGAAGCAAGAAAATAC 325
Db
       181 CCTCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACCCAAGAA 240
Qу
          326 CCCCTCCATCAACTTCTTCAAGATGAATCTTCTTACATTTTCGTAAGTGTTACTCAAGAA 385
Db
       241 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGATCTTCGGCTTTTTCAA 300
Qу
          386 GCAGAAAGGGAAGAATTTTTTGATGAAACAAGACGACTTTGTGACCTTCGGCTTTTTCAA 445
Db
       301 CCATTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 360
Qу
          446 CCCTTTTTAAAAGTAATTGAACCAGTAGGCAACCGTGAAGAAAAGATCCTCAATCGAGAA 505
Db
       361 ATTGGTTTTGCTATCGGCATGCCAGTGTGCGAATTTGATATGGTTAAAGATCCTGAAGTA 420
Qу
          506 ATTGGTTTTGCTATCGGCATGCCAGTGTGTGAATTTGATATGGTTAAAGATCCAGAAGTA 565
Db
       421 CAGGACTTCCGAAGAAATATTCTTAATGTTTGTAAAGAAGCTGTGGATCTTAGGGATCTT 480
Qу
          566 CAGGACTTCCGAAGAATATTCTGAACGTTTGTAAAGAAGCTGTGGATCTTAGGGACCTC 625
Db
Qу
       481 AATTCACCTCATAGTAGAGCAATGTATGTCTATCCGCCACATGTAGAATCTTCACCAGAG 540
          626 AATTCACCTCATAGTAGAGCAATGTATGTCTATCCTCCAAATGTAGAATCTTCACCAGAA 685
Db
       541 CTGCCAAAGCACATATATAATAAATTGGATAGAGGCCAAATAATAGTGGTGATTTGGGTA 600
Qу
           Db
       686 TTGCCAAAGCACATATATAATAAATTAGATAAAGGGCAAATAATAGTGGTGATCTGGGTA 745
```

Db

Qу

1406 GAGGAACACTGTCCATTGGCATGGGGAAATATAAACTTGTTTGATTACACAGACACTCTA 1465

1321 GTATCTGGAAAAATGGCTTTGAATCTTTGGCCAGTACCTCATGGATTAGAAGATTTGCTG 1380

Db	1466		1525
Qу	1381	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1440
Db	1526	AACCCTATTGGTGTTACTGGATCAAATCCAAATAAAGAAACTCCATGCTTAGAGTTGGAG	1585
Qy	1441	TTTGACTGGTTCAGCAGTGTGGTAAAGTTCCCAGATATGTCAGTGATTGAAGAGCATGCC	1500
Db	1586		1645
Qy	1501	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1560
Db	1646	AATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGACTGAGTAACAGA	1705
Qу	1561	CTAGCTAGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACA	1620
Db	1706		1765
Qу	1621	00110111 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1	1680
Db	1766	CGAGATCCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACAC	1825
Qу	1681		1740
Db	1826	TATTGTGTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTG	1885
Qу	1741	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1800
Db	1886	AGAGATGAAGTAGCCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAA	1945
Qу	1801	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	1860
Db	1946	CAGGCTATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTT	2005
Qу	1861	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	1920
Db	2006	CGGTGCTTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTA	2065
Qу	1921	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	1980
Db	2066	CAGGTCCTAAAATATGAACAATATTTGGATAACTTGCTTG	2125
Qу	1981	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2040
Db	2126	GCATTGACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTTAAAATCTGAGATGCAC	2185
Qy	2041	AATAAAACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGG	2100

Qy	2821	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	2880
Db	2966	TTTTTGGATCACAAGAAGAAAAATTTGGTTATAAACGAGAACGTGTGCCATTTGTTTTG	3025
Qy	2881	ACACAGGATTTCTTAATAGTGATTAGTAAAGGAGCCCAAGAATGCACAAAGACAAGAGAA	2940
Db	3026		3085
Qy	2941	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3000
Db	3086	TTTGAGAGGTTTCAGGAGATGTGTTACAAGGCTTATCTAGCTATTCGACAGCATGCCAAT	3145
Qу	3001	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3060
Db	3146	CTCTTCATAAATCTTTTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTACAATCTTTT	3205
Qу	3061	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3120
Db	3206	GATGACATTGCATACATTCGAAAGACCCTAGCCTTAGATAAAACTGAGCAAGAGGCTTTG	3265
Qy	3121	GAGTATTTCATGAAACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGGAT	3180
Db	3266		3325
Qy	3181	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTG-AAAGATAACTGAGAAAATGAA	3239
Db	3326	TGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGATAACTGAGAAAATGAA	3385
Qy	3240	AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC	3299
Db	3386	AGCTCACTCTGGATTCCACACTGCACTGTTAATAACTCTCAGCAGGCAAAGACCGATTGC	3445
Qy	3300	ATAGGAATTGCACAATCCATGAACAGCATTAG-ATTTACAGCAAGAACAGAAATAAAATA	3358
Db	3446		3505
Qy	3359	CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT	3418
Db	3506	CTATATAATTTAAATAATGTAAACGCAAACAGGGTTTGATAGCACTTAAACTAGTTCATT	3565
Qу	3419	TCAAAA 3424	
Db	3566	TCAAAA 3571	

Search completed: January 18, 2011, 22:57:20

Job time : 1700 secs

SCORE Search Results Details for Application 10591347 and Search Result 20110118_143624_seq2sub1633a.rng.